HOLLISTON, Mass., Harvard Bioscience, Inc. (Nasdaq:HBIO), a global developer, manufacturer, and marketer of a broad range of tools to advance life science research and regenerative medicine, today announced that it has acquired the business of AHN Biotechnologie GmbH through its wholly owned Biochrom Ltd. subsidiary.

AHN is a privately held manufacturer of plastic consumable laboratory products including pipette tips. This acquisition is complementary to the current Biochrom product line of molecular biology instruments.

David Green, President of Harvard Bioscience, commented, “The acquisition of AHN Biotechnologie gives us a product line that is complimentary to the current Biochrom product line and also gives us a base of business in Germany for our entire molecular biology business. AHN will add approximately $2.5m in annual revenue and we expect this acquisition to be accretive to 2012 earnings per share.”

About Harvard Bioscience

Harvard Bioscience (“HBIO”) is a global developer, manufacturer and marketer of a broad range of specialized products, primarily apparatus and scientific instruments, used to advance life science research and regenerative medicine. HBIO sells products to thousands of researchers in over 100 countries primarily through our 850 page catalog (and various other specialty catalogs), our website, through distributors, including GE Healthcare, Thermo Fisher Scientific and VWR, and via our field sales organization. HBIO has sales and manufacturing operations in the United States, the United Kingdom, Germany, Sweden and Spain with additional facilities in France and Canada. For more information, please visit www.harvardbioscience.com.